The day Medicare officials began discussing whether to set new coverage limits on a costly new prostate-cancer treatment, the official in charge emailed three colleagues to put a “close hold” on the process. That meant: Keep quiet until an announcement later that month.
Yet by the end of that same day, June 7, 2010, shares of the company that made the treatment, Dendreon Corp. , had plunged 10%. Before long, federal investigators took notice.
‘Enforcement 40’ for 2020
Join Us On LinkedIn
Join the Securities Litigation and Enforcement Group on LinkedIn